血清miR-142-3p和miR-493-5p水平在原发性肝癌早期诊断及病情评估中的应用价值

摘要/Abstract

摘要： 目的探讨血清微小RNA(miR)-142-3p和miR-493-5p的表达水平在原发性肝癌(PHC)早期诊断及病情评估中的应用价值。方法选取2020年6月—2023年8月期间保定市第二中心医院收治的86例PHC患者(PHC组),并选取同期50例自身免疫性肝炎患者(良性组),另选取同期健康体检者86例作为对照组。实时荧光定量聚合酶链式反应(qRT-PCR)检测血清miR-142-3p和miR-493-5p表达水平。采用受试者工作特征(ROC)曲线分析血清miR-142-3p和miR-493-5p对PHC早期诊断及病情评估的价值。结果 PHC组血清中miR-142-3p(0.79±0.21)、miR-493-5p表达水平(0.83±0.22)显著低于良性组[(0.89±0.11)、(0.92±0.10)]和对照组[(1.01±0.12)、(1.02±0.13)],差异有统计学意义(P<0.05);PHC患者血清中miR-142-3p、miR-493-5p水平在肿瘤直径≥3 cm显著低于＜3 cm、有门静脉血管侵犯显著低于无门静脉血管侵犯、有远处转移显著低于无远处转移,差异具有统计学意义(P<0.05);Ⅲ期和Ⅳ期PHC患者血清中miR-142-3p[(0.76±0.06)、(0.67±0.05)]、miR-493-5p表达水平[(0.81±0.09)、(0.70±0.06)]显著低于Ⅰ～Ⅱ期[(0.89±0.09)、(0.93±0.11)],差异具有统计学意义(P<0.05)。ROC曲线分析发现,血清miR-142-3p和miR-493-5p对PHC早期诊断的ROC结果显示,血清miR-142-3p和miR-493-5p联合对PHC早期诊断的AUC为0.910显著高于二者单独诊断(Z=3.184、2.739,均P<0.05)。血清miR-142-3p和miR-493-5p联合对病情评估的AUC为0.940显著高于二者单独评估(Z=1.994、2.470,均P<0.05)。结论 miR-142-3p和miR-493-5p在PHC患者血清中均呈低表达,可作为诊断PHC及病情评估的血清标志物,两者联合检测能够显著提高PHC诊断及病情评估效能。

关键词: 微小RNA-142-3p, 微小RNA-493-5p, 原发性肝癌, 诊断, 病情

Abstract: Objective To explore the application value of serum microRNA(miR)-142-3p and miR-493-5p expression levels in the early diagnosis and disease assessment of primary hepatocellular carcinoma (PHC). Methods From June 2020 to August 2023, eighty-six PHC patients admitted to Baoding Second Central Hospital were collected as the PHC group, and 50 patients with autoimmune hepatitis were collected during the same period of time as the benign group. Additionally, 86 healthy individuals who underwent physical examination were collected as control group. Real-time quantitative fluorescence polymerase chain reaction (qRT-PCR) was used to measure the serum levels of miR-142-3p and miR-493-5p. Receiver operating characteristic (ROC) curve was applied to analyze the value of serum miR-142-3p and miR-493-5p in the early diagnosis and disease assessment of PHC. Results The expression levels of miR-142-3p (0.79±0.21) and miR-493-5p (0.83±0.22) in the serum of the PHC group were significantly lower than those of the benign group [(0.89±0.11) and (0.92±0.10), respectively] and control group [(1.01±0.12) and (1.02±0.13), respectively] (P<0.05). The levels of serum miR-142-3p and miR-493-5p in PHC patients with tumor diameter ≥3cm, portal vein invasion, distant metastasis were obviously lower than those in patients with tumor diameter <3 cm, non-portal vein invasion, and non-distant metastasis (P<0.05); the expression levels of miR-142-3p [(0.76±0.06), (0.67±0.05)] and miR-493-5p [(0.81±0.09), (0.70±0.06)] in the serum of patients with stage III and IV PHC, respectively, were significantly lower than those in stages I-II [(0.89±0.09), (0.93±0.11)] (P<0.05). The AUC of the combination of serum miR-142-3p and miR-493-5p for early diagnosis of PHC was 0.910, which was obviously higher than that of the two alone (Z=3.184, 2.739, all P<0.05). The AUC of serum miR-142-3p combined with miR-493-5p for disease assessment was 0.940, which was obviously higher than those of the two assessment alone (Z=1.994, 2.470, all P<0.05). Conclusion MiR-142-3p and miR-493-5p are both low expressed in the serum of PHC patients, which can be used as serum biomarkers for the diagnosis and assessment of PHC. A combined detection of these two miRs can significantly improve the diagnostic and assessment efficiency of PHC.

Key words: Micro RNA-142-3p, Micro RNA-493-5p, Primary hepatocellular carcinoma, Diagnosis, Disease condition

王会哲, 卢双动, 王谦, 刘龙艳, 汪明泉. 血清miR-142-3p和miR-493-5p水平在原发性肝癌早期诊断及病情评估中的应用价值[J]. 肝脏, 2024, 29(10): 1205-1208.

WANG Hui-zhe, LU Shuang-dong, WANG Qian, LIU Long-yan, WANG Ming-quan. The application value of serum microRNA-142-3p and miR-493-5p expression levels in the early diagnosis and disease assessment of primary hepatocellular carcinoma[J]. Chinese Hepatolgy, 2024, 29(10): 1205-1208.

/ 推荐

参考文献

[1] 汪玲, 张青, 芮火飞, 等. AFP、AFP-L3%与IGF-1联合检测在原发性肝癌诊断中的价值[J]. 标记免疫分析与临床,2023,30:982-986.
[2] Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classificationt[J]. Adv Cancer Res,2021,149:1-61.
[3] Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment[J]. Cells,2020,9:1370-1384.
[4] 刘栋, 曹旭, 周昀. 血清肿瘤标志物单独以及联合检测在原发性肝癌中的诊断价值研究[J]. 系统医学,2023,8:63-65,70.
[5] 李子英, 卢再鸣, 赵相轩, 等. 微小RNA与原发性肝癌的研究进展[J]. 中国肝脏病杂志(电子版),2015,7:8-10.
[6] Fu Y, Sun LQ, Huang Y, et al. miR-142-3p inhibits the metastasis of hepatocellular carcinoma cells by regulating HMGB1 gene expression[J]. Curr Mol Med,2018,18:135-141.
[7] Yasukawa K, Liew LC, Hagiwara K, et al. MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion[J]. Cancer Sci,2020,111:869-880.
[8] 中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治的专家共识[J]. 肿瘤,2009,29:295-304.
[9] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015)[J]. 临床肝胆病杂志,2016:9-22.
[10] Yuan LT, Lee WJ , Yang YC, et al. Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122[J]. Cancers,2021,13:2376-2384.
[11] Siu L, Brody J, Gupta S, et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors[J]. J Immunother Cancer,2020,8:1095-1113.
[12] Zhang Y, Yang Y, Zhang Y, et al. lncRNA ST8SIA6AS1 facilitates proliferation and invasion in liver cancer by regulating miR1423p[J]. Exp Ther Med,2021,22:1348-1356.
[13] Xiao P, Liu WL. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma[J]. Int J Clin Exp Pathol,2015,8:10800-108007.
[14] 苏红娥, 钟庆吉, 符春丽, 等. 血清miR-153和miR-142-3p表达在宫颈癌诊断和预后评估中的价值[J]. 肿瘤学杂志,2020,26:972-976.
[15] Zhu K, Zhang Z, Zhang H, et al. MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells[J]. Artif Cells Nanomed Biotechnol,2020,48:415-424.
[16] Yang G, Xu Q, Wan Y, et al. Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation[J]. Cell Signal,2021,86:110065-110078.
[17] Zhao J, Xu T, Wang F, et al. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73[J]. Biomed Pharmacother,2017,90:744-751.
[18] 张羽, 张璨, 章伟玲. 长链非编码RNA NR2F1-AS1靶向微小RNA-493-5p表达调控卵巢癌细胞增殖及凋亡的机制研究[J]. 实用临床医药杂志,2023,27:30-34.
[19] 刘绍祖, 黄晓华. 前列腺癌组织中miR-449a、miR-493-5p表达与临床病理参数及预后的关系[J]. 中国性科学,2021,30:33-36.
[20] 张莉, 华毛, 刘浩明. miR-493-5p下调METTL3表达影响鼻咽癌细胞增殖、迁移和侵袭的研究[J]. 河北医药,2022,44:815-819.